Reply
Am J Ophthalmol
.
2017 Nov:183:166-167.
doi: 10.1016/j.ajo.2017.09.014.
Epub 2017 Sep 22.
Authors
Samaneh Davoudi
1
,
Nazanin Ebrahimiadib
2
,
Cagla Yasa
1
,
Damla D Sevgi
1
,
Ramak Roohipoor
2
,
Evangelia Papavasilieou
1
,
Jason Comander
1
,
Lucia Sobrin
1
Affiliations
1
Boston, Massachusetts.
2
Boston, Massachusetts, and Tehran, Iran.
PMID:
28947061
DOI:
10.1016/j.ajo.2017.09.014
No abstract available
Publication types
Letter
Comment
MeSH terms
Autoimmune Diseases* / drug therapy
Humans
Retinal Diseases* / drug therapy
Rituximab
Substances
Rituximab